Aprogen에이프로젠
007460 · KOSPI · ₩007460 · 에이프로젠
- Market cap
- ₩49B
- Enterprise value
- ₩191B
- P/E
- —
- P/B
- 0.8×
- Dividend yield
- 0.0%
- ROE
- −138.0%
- Net margin
- −60.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−88.2% from the high
₩1,841Today: ₩1,906 – ₩1,944₩16,231
Returns
- 1W−2.0%
- 1M−4.8%
- 3M−12.0%
- 6M−62.2%
- YTD−84.1%
- 1Y−82.1%
- Volume today
- 38,622
- 0.3× the 20-day average
- Traded today
- ₩74M
- Listed shares
- 25,650,015
- EPS (12 months)
- −₩3,257
- Earnings yield −170.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-5.7% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Aprogen stock overview
Aprogen (에이프로젠, KRX: 007460) is listed on KOSPI, in the Biotech & Pharma sector. A Korean company with several business segments. Its shares closed at ₩1,914 on Oct 27, 2026, down 0.73% on the day, giving it a market value of ₩49B.
Key facts
- Market cap
- ₩49B
- Sector
- Biotech & Pharma
- Latest price change
- −0.73%
- As of
- Oct 27, 2026
- Main business
- A Korean company with several business segments.
Quick answers about Aprogen
- What does Aprogen do?
- A Korean company with several business segments. Its metal segment provides Hardfacing, a process that welds harder, more corrosion- and wear-resistant metal onto machine parts to extend their life, serving steel mills, thermal power plants and cement factories, and also sells steel products. It manufactures and sells pharmaceuticals, including prescription drugs and cosmetics, and insulation products such as Nukon systems for nuclear power plants and Foamglas insulation.
- What is the market cap of Aprogen?
- The market capitalisation of Aprogen was ₩49B at the close on Oct 27, 2026.
- Who are the largest shareholders of Aprogen?
- According to the latest official filings, the largest reported holders are Jibase (85.61%, as of Oct 23, 2026); Harvest Roses (14.18%, as of Sep 9, 2026); Nexconix (8.04%, as of Apr 17, 2026).
- When is the next earnings report from Aprogen?
- Korean companies rarely announce results dates in advance. Based on when Aprogen filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Aprogen?
- Yes. The National Pension Service held 0.76% of Aprogen shares as of Dec 31, 2025.
Company profile
A Korean company with several business segments. Its metal segment provides Hardfacing, a process that welds harder, more corrosion- and wear-resistant metal onto machine parts to extend their life, serving steel mills, thermal power plants and cement factories, and also sells steel products. It manufactures and sells pharmaceuticals, including prescription drugs and cosmetics, and insulation products such as Nukon systems for nuclear power plants and Foamglas insulation. Through its biopharmaceutical division it develops, manufactures and sells protein-based biologics, mainly biosimilars and new biologic drugs, with a Remicade biosimilar sold in Japan. Its subsidiaries make semiconductor equipment parts and renewable energy systems such as geothermal heating and cooling and fuel cells.
Written by AI from the company's latest annual report.
- Korean name
- 에이프로젠
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김재섭
- Founded
- Nov 1971
- Listed
- Jul 1995
- Listed shares
- 25,650,015
- Fiscal year ends
- Month 12
- Website
- www.aprogen.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- 5%+ holding reportOct 23, 2026
- Decision on Provision of Collateral to Another Party (material management matter of subsidiary)Oct 8, 2026
- 5%+ holding reportOct 8, 2026
- Decision on Loan Provision (Major Management Matters of Subsidiary)Sep 23, 2026
- Amended: Rights offering (paid-in capital increase) decisionSep 23, 2026
Titles in Korean until English translations are added.
Also known as: Aprogen / 에이프로젠 / 007460 / KRX:007460
Source: KRX statistical information